VEA
ATRA icon

Virtus ETF Advisers’s Atara Biotherapeutics ATRA Stock Holding History

Virtus ETF Advisers’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,043
Closed -$75.6K – 441
2023
Q1 		$75.6K Sell
1,043
-401
-28% -$38.9K 0.04% 393
2022
Q4 		$118K Buy
1,444
+634
+78% +$66.1K 0.06% 420
2022
Q3 		$77K Buy
810
+6
+0.7% +$674 0.03% 429
2022
Q2 		$157K Buy
804
+409
+104% +$66.8K 0.06% 315
2022
Q1 		$92K Sell
395
-23
-6% -$7.32K 0.04% 315
2021
Q4 		$165K Sell
418
-162
-28% -$68.2K 0.06% 307
2021
Q3 		$259K Sell
580
-30
-5% -$10.7K 0.11% 215
2021
Q2 		$237K Buy
610
+99
+19% +$35.3K 0.1% 226
2021
Q1 		$184K Buy
511
+8
+2% +$3.54K 0.08% 334
2020
Q4 		$247K Sell
503
-811
-62% -$374K 0.1% 316
2020
Q3 		$426K Sell
1,314
-180
-12% -$61.3K 0.22% 156
2020
Q2 		$544K Buy
1,494
+563
+60% +$142K 0.26% 137
2020
Q1 		$198K Sell
931
-136
-13% -$43.2K 0.08% 276
2019
Q4 		$439K Buy
1,067
+605
+131% +$209K 0.07% 227
2019
Q3 		$163K Sell
462
-26
-5% -$9.7K 0.03% 273
2019
Q2 		$245K Buy
+488
New +$344K 0.05% 279
2016
Q4 		– Sell
-506
Closed -$271K – 181
2016
Q3 		$271K Hold
506
– – 0.13% 110
2016
Q2 		$285K Buy
506
+49
+11% +$23.5K 0.21% 67
2016
Q1 		$218K Sell
457
-28
-6% -$12.6K 0.3% 72
2015
Q4 		$321K Buy
+485
New +$367K 0.88% 32

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtus ETF Advisers's ATRA Position: Q2 2023 in Review

Virtus ETF Advisers sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 1,043 shares — an estimated $75.6K sold.

Virtus ETF Advisers first reported a position in ATRA in Q4 2015 and held it in 20 quarters. The position peaked at $544K in Q2 2020. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

  • Virtus ETF Advisers reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,043 Atara Biotherapeutics shares in Q2 2023, an estimated $75.6K.
  • Virtus ETF Advisers first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 20 quarters.
  • Virtus ETF Advisers's Atara Biotherapeutics position peaked at $544K in Q2 2020.
  • 118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.